We are live on ! Find out more
PSTX

Poseida Therapeutics, Inc. Common Stock
PSTX

Delisted

PSTX was delisted on the 7th of January, 2025.

Back to rankings

89 hedge funds and large institutions have $226M invested in Poseida Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 28 increasing their positions, 16 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

947% more call options, than puts

Call options by funds: $1.26M | Put options by funds: $120K

233% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 9

75% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 16

62% more capital invested

Capital invested by funds: $140M → $226M (+$86.5M)

31% more funds holding

Funds holding: 68 → 89 (+21)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
89
Holders Change
+21
Holders Change %
+30.88%
% of All Funds
1.43%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
30
Increased
28
Reduced
16
Closed
9
Calls
$1.26M
Puts
$120K
Net Calls
+$1.14M
Net Calls Change
+$992K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$6.83M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$2.64M
3
Marshall Wace
Marshall Wace
United Kingdom
+$2.34M
4
PBA
Paradigm Biocapital Advisors
New York
+$1.67M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$1.57M

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$3.2M
2
PA
Perceptive Advisors
New York
-$2.65M
3
SCM
Silverarc Capital Management
Massachusetts
-$1.48M
4
Citadel Advisors
Citadel Advisors
Florida
-$1.44M
5
SFM
Sphera Funds Management
Israel
-$1.06M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
26
Citigroup
New York
$867K +$735K +160,829 +5,651%
State Street
27
State Street
Massachusetts
$835K +$295K +64,600 +69%
CAM
28
Crown Advisors Management
California
$795K – – –
Goldman Sachs
29
Goldman Sachs
New York
$682K +$249K +54,569 +74%
XT
30
XTX Topco
Cayman Islands
$657K +$493K +107,856 +667%
HighTower Advisors
31
HighTower Advisors
Illinois
$615K – – –
Morgan Stanley
32
Morgan Stanley
New York
$562K +$167K +36,628 +53%
GCP
33
GSA Capital Partners
United Kingdom
$506K +$436K +95,469 New
CSS
34
Cubist Systematic Strategies
Connecticut
$453K +$320K +70,033 +452%
Northern Trust
35
Northern Trust
Illinois
$453K +$92.8K +20,298 +31%
DekaBank Deutsche Girozentrale
36
DekaBank Deutsche Girozentrale
Germany
$412K – – –
Jane Street
37
Jane Street
New York
$373K +$322K +70,353 New
RC
38
RBF Capital
California
$372K – – –
Two Sigma Investments
39
Two Sigma Investments
New York
$351K +$162K +35,408 +115%
CIC
40
Cornercap Investment Counsel
Georgia
$350K – – –
JF
41
Jump Financial
Illinois
$344K +$297K +64,895 New
Walleye Capital
42
Walleye Capital
New York
$341K +$294K +64,371 New
CC
43
Callan Capital
California
$330K +$285K +62,347 New
Barclays
44
Barclays
United Kingdom
$308K +$122K +26,650 +85%
Bank of New York Mellon
45
Bank of New York Mellon
New York
$259K -$3.13K -685 -1%
JIC
46
Johnson Investment Counsel
Ohio
$248K – – –
MA
47
MCF Advisors
Kentucky
$227K -$41.1K -9,000 -17%
Citadel Advisors
48
Citadel Advisors
Florida
$221K -$1.44M -315,025 -88%
Qube Research & Technologies (QRT)
49
Qube Research & Technologies (QRT)
United Kingdom
$201K +$63.6K +13,916 +58%
6CM
50
683 Capital Management
New York
$196K +$169K +36,966 New
1
2
3 4

PSTX Hedge Fund Activity: Q4 2022 in Review

89 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q4 2022, worth a combined $226M — up 62% from $140M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new PSTX positions and 9 closed out — a net gain of 21 holders — while 28 added to existing stakes and 16 trimmed.

The largest buyer was Millennium Management, adding an estimated $6.83M. The largest seller was Cormorant Asset Management, cutting an estimated $3.2M.

  • 89 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q4 2022, up from 68 in Q3 2022.
  • Funds reported $226M of Poseida Therapeutics, Inc. Common Stock stock for Q4 2022, up 62% quarter-over-quarter.
  • 30 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q4 2022 and 9 closed out, a net change of +21 holders.
  • The largest Poseida Therapeutics, Inc. Common Stock buyer in Q4 2022 was Millennium Management, an estimated $6.83M added.
  • The largest Poseida Therapeutics, Inc. Common Stock seller in Q4 2022 was Cormorant Asset Management, an estimated $3.2M sold.

Based on aggregated 13F filings for Q4 2022.